- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02900768
Effects of Exercise on Allogeneic Stem Cell Transplant (Ex-BMT)
Evaluating Effects on Quality of Life of a Partially Supervised Exercise Program Following Allogeneic Stem Cell Transplantation
Although allogeneic haematopoietic stem cell transplant (AlloHSCT) is a curative treatment option for malignant hematological diseases, it is also associated with significant morbidity such as graft versus host disease, infections, and immune complications. Moreover, long-term survivors are likely to have reduced physical performance and functioning due to deconditioning, sarcopenia, and bone loss, and particularly high levels of fatigue and psycho-social stress, all of which negatively impact patients' quality of life.
Purpose: To conduct a randomized controlled, single site trial investigating whether a partially supervised exercise intervention in the first 100 days post alloHSCT patients will result in improved quality of life at Day 100 post-transplant compared to standard of care treatment. Secondary objectives will investigate the effect of an exercise intervention on muscle strength, cardiorespiratory fitness, mobility, bone mineral density, body composition, exercise, and immunological/inflammatory biomarkers compared to standard of care.
Procedure: 120 patients receiving alloHSCT will be baseline tested, and then randomized into an Exercise Intervention Group or Standard of Care Control Group.
Study Overview
Detailed Description
This is a randomized non-blinded single centre prospective clinical trial designed to evaluate the efficacy and safety of a partially-supervised progressive exercise intervention among patients undergoing alloHSCT compared to a self-directed exercise program. Approximately 120 patients will be enrolled. Following completion of all baseline data collection, participants will be randomized 1:1 to the intervention group or the control group.
Patients in the intervention group will receive an exercise manual with background information, descriptions for different resistance and aerobic exercises, and instructions for tailoring the intensity of exercise. All patients will receive Therabands™ for resistance exercises and have access to a stationary bicycle for aerobic exercises with practical introduction by an exercise specialist. The partially supervised intervention is a progressive program with a goal of three aerobic and two resistance exercise sessions per week.
Aerobic exercise will consist of 10-30 minutes of bicycling using a stationary bike (supervised or unsupervised) or brisk walking, following the Borg Scale of Rate of Perceived Exertion (RPE). Resistance exercise will include exercise for the upper and lower extremities with Therabands™. Exercise will be adapted based on the participant's clinical status for safety and ability to perform exercises. At the weekly supervised session, the exercise specialist will provide adequate progression of exercises, and review adherence to the intervention and provide support for questions and overcoming identified barriers to adherence.
Participants assigned to the control group will receive our current standard of care. They will be reviewed by the ward physiotherapist on admission to hospital and encouraged to maintain physical activity by walking around the inpatient unit during their inpatient hospitalization. As per standard of care, the physiotherapist will be available on an as needed basis in both the inpatient and outpatient settings.
Timely assessments of outcome measures outlined in the "Outcome Measures" section will be conducted for both groups.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z1M9
- Vancouver General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients undergoing allogeneic stem cell transplantation (including related, unrelated, cord blood or haploidentical allogeneic transplant) for any indication through the Leukemia/BMT Program of British Columbia.
- Age greater than or equal to 18 years.
- Able to provide written informed consent.
Exclusion Criteria:
- Severe cardiac disease including symptomatic congestive heart failure (New York Heart Association Class III or IV), unstable angina pectoris, or an unstable cardiac arrhythmia.
- Orthopedic illness which limits ability to conduct aerobic exercise (walking or biking).
- Not meeting eligibility criteria to proceed with allogeneic stem cell transplantation as per the Leukemia/BMT Program of BC.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Exercise Group
Patients in the intervention group will receive supervised and unsupervised exercise program after their bone marrow transplant.
|
Combination of resistance and aerobic exercises for 100 days.
|
|
No Intervention: Control Group
Patient will receive standard of care within the hospital as an inpatient and outpatient after their bone marrow transplant.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Quality of Life
Time Frame: Baseline, Day 100 post-transplant
|
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. To investigate if a partially supervised exercise intervention in alloHSCT patients will result in differences in quality of life at Day 100 post transplant compared to the standard of care control group. |
Baseline, Day 100 post-transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Quality of Life
Time Frame: Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
EuroQol (EQ)-5 Dimensions (5D) -3 Level (3L) Questionnaire.
|
Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
|
Changes in Grip Strength
Time Frame: Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
Using a handheld dynamometer, measured in kg.
|
Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
|
Changes in 30-Second Chair Stand
Time Frame: Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
Number of chair stands one can perform in 30 seconds.
|
Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
|
Changes in 6-Minute Walk Test
Time Frame: Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
Distance (meters) someone can walk in 6 minutes between two cones separated by 30 meters.
|
Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
|
Changes in Timed Up and Go
Time Frame: Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
Time taken for someone to stand up from a chair, walk 3 meters, turn around, walk back to the chair, and sit sound.
|
Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
|
Changes in Exercise Capacity
Time Frame: Baseline, Day 100, 365, and 730 post-transplant
|
Exercise Treadmill Test via Bruce or Modified Bruce Protocol.
METs and estimated peak oxygen uptake (VO2) will be determined.
|
Baseline, Day 100, 365, and 730 post-transplant
|
|
Changes in Cardiopulmonary Function
Time Frame: Baseline, Day 100, 365, and 730 post-transplant
|
Left ventricular ejection fraction vs radionuclide ventriculography (MUGA) or echocardiography.
|
Baseline, Day 100, 365, and 730 post-transplant
|
|
Changes in Physical Activity Levels - Accelerometry
Time Frame: Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
Accelerometry counts converted minutes/week of moderate-to-vigorous activity and sedentary activity and METS.
Godin Leisure-Time Exercise Questionnaire.
|
Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
|
Changes in Physical Activity Levels - Questionnaire
Time Frame: Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
Godin Leisure-Time Exercise Questionnaire.
Total leisure activity score is calculated.
|
Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
|
Changes in Body Composition Analysis
Time Frame: Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
Height (cm), weight (m), and waist/hip circumference (cm) will be measured.
|
Baseline, Hospital Discharge (approximately +30 days post-transplant), Day 60, 100, 365, and 730 post-transplant
|
|
Changes in Bone Mineral Density Analysis
Time Frame: Baseline, Day 100, 365, and 730 post transplant
|
Bone mineral density testing will be performed using a Dual-Energy X-Ray Absorptiometry (DXA).
|
Baseline, Day 100, 365, and 730 post transplant
|
|
Changes in Immune Biomarkers
Time Frame: Baseline, Day 100, 365, and 730 post-transplant
|
A collective blood test will be done to determine the composition of white blood cells (total, lymphocytes, and subsets of T-Lymphocytes).
|
Baseline, Day 100, 365, and 730 post-transplant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alina Gerrie, MD, FRCPC, British Columbia Cancer Agency
- Principal Investigator: Raewyn Broady, MBChB, FRCPC, British Columbia Cancer Agency
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H16-00112
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Malignancy
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Peking University People's HospitalSanofiRecruitingHematological MalignancyChina
-
Beckman Coulter, Inc.Completed
-
Fate TherapeuticsTerminatedHematological MalignancyUnited States
-
University Hospital, Strasbourg, FranceUnknownHematological MalignancyFrance
-
Universitaire Ziekenhuizen KU LeuvenInstitutul Clinic FundeniCompletedHematological MalignancyBelgium, Romania
-
SanofiCompletedHematological MalignancyFrance, United States, Argentina, Belgium, Brazil, Chile, Finland, Greece, Israel, Italy, Mexico, Peru, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
-
University of CopenhagenZealand University HospitalEnrolling by invitationHematological MalignancyDenmark
-
Washington University School of MedicineBarnes-Jewish HospitalTerminatedHematological MalignancyUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHematological MalignancyUnited States
Clinical Trials on Exercise
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
University of Texas, El PasoRecruitingKnee Osteoarthritis | Knee Pain Chronic | Central Pain SyndromeUnited States
-
Aksaray University Training and Research HospitalCompletedExercise Training | Lactate Blood Increase | Cognitive Functions | BDNFTurkey (Türkiye)
-
Bayero University Kano, NigeriaCompletedChronic Low Back PainNigeria
-
University of Alabama at BirminghamCompletedCystic FibrosisUnited States
-
Center for Health, Exercise and Sport Sciences,...CompletedSedentary LifestyleSerbia
-
Heitor Moreno JuniorUnknown
-
Middle East Technical UniversityCompletedOsteoarthritis | Degenerative Lesion of Articular Cartilage of Knee | Articular Cartilage Disorder of KneeTurkey
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
University of LisbonFundação para a Ciência e a TecnologiaActive, not recruiting